# Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

> **NCT02725112** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pregabalin ER
- **DRUG:** Pregabalin ER
- **DRUG:** Pregabalin ER
- **DRUG:** Pregabalin ER
- **DRUG:** Pregabalin ER
- **DRUG:** Pregabalin ER

## Key facts

- **NCT ID:** NCT02725112
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-12
- **Primary completion:** 2016-05-22
- **Final completion:** 2016-06-17
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02725112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02725112, "Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02725112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*